Publications by authors named "Koo Wilson"

Claim this Profile
A
Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria.
Regis Peffault de Latour, Austin Kulasekararaj, David Dingli, Koo Wilson, Piotr Wojciechowski

Eur J Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK.
Nichola Cooper, Sebastian Guterres, Michał Pochopień, Koo Wilson, Sam James

J Mark Access Health Policy· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison.
Koo Wilson, Francesca Chiodi, Abby Paine, Zalmai Hakimi, Victoria Ward

Adv Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health-related quality of life and productivity.
Koo Wilson, Carly Rich, Zalmai Hakimi, Regina Horneff, Jesse Fishman

Eur J Haematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The disease burden of paroxysmal nocturnal hemoglobinuria in Denmark: Epidemiology, survival, healthcare resource utilization, costs, treatment gaps, and labor market attachment.
Carly Rich, Koo Wilson, Jens Olsen, Mikkel Pedersen, Henrik Frederiksen

Eur J Haematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort.
Alessandro Lucchesi, Barbara Lovrencic, Vickie McDonald, Adrian Newland, Mervyn Morgan, Koo Wilson

Hematology· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
Raymond Wong, Jesse Fishman, Koo Wilson, Michael Yeh, Mohammed Al-Adhami

Adv Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study).
A J Gerard Jansen, Vickie McDonald, Adrian Newland, Mervyn Morgan, Mieke Bastiaanse, Koo Wilson

Hematology· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA.
Jesse Fishman, Koo Wilson, Aleksandra Drzewiecka, Michał Pochopień, David Dingli

J Comp Eff Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data.
Jens Panse, Koo Wilson, Jesse Fishman, Piotr Wojciechowski, Marlena Wdowiak

Eur J Haematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France.
Piotr Wojciechowski, Marlena Wdowiak, Zalmai Hakimi, Koo Wilson, Jesse Fishman

J Comp Eff Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
Raymond Wong, Jesse Fishman, Koo Wilson, Michael Yeh, Mohammed Al-Adhami

Adv Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective.
Flore Sicre de Fontbrune, Pascale Burmester, Maria Piggin, Joana E Matos, Halley Costantino, Koo Wilson

Hematology· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life.
Jens Panse, Flore Sicre de Fontbrune, Pascale Burmester, Maria Piggin, Joana E Matos, Koo Wilson

Eur J Haematol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting.
Zalmai Hakimi, Koo Wilson, Eoin McAughey, Michal Pochopien, Piotr Wojciechowski

J Comp Eff Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study).
Vickie McDonald, Adrian Newland, Mervyn Morgan, Koo Wilson, Jameel Nazir

Hematology· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and treatment of immune thrombocytopenia in Europe: a qualitative observational study.
Edgar A Pogna, Simon Middleton, Jameel Nazir, Leah Ralph, Koo Wilson

Hematology· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis.
Piotr Wojciechowski, Koo Wilson, Jameel Nazir, Iwona Pustułka, Anna Tytuła

Adv Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data.
Ash Bullement, Samuel Thomas McMordie, Anthony James Hatswell, Nanxin Li, Koo Wilson

Pharmacoecon Open· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A analysis of Dupuytren contracture treated with collagenase across disease stages.
Gary M Pess, Maj Sundbom, Koo Wilson, Daniel Lindqvist, Lars B Dahlin

J Plast Surg Hand Surg· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Nathaniel Henry, Jelena Jovanović, Max Schlueter, Persefoni Kritikou, Koo Wilson

J Med Econ· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the predictive value of pain intensity on costs and resources utilization in patients with peripheral neuropathic pain.
Concepción Pérez, Ana Navarro, María T Saldaña, Koo Wilson, Javier Rejas

Clin J Pain· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.
Dawn Lee, Koo Wilson, Ron Akehurst, Martin R Cowie, Faiez Zannad

Heart· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
Kevin Lock, Koo Wilson, Daniel Murphy, Juan Antonio Riesco

Expert Opin Pharmacother· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and future avoidable cost of smoking--estimates for Sweden 2007.
Kristian Bolin, Benny Borgman, Christina Gip, Koo Wilson

Health Policy· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis